0000000000542967

AUTHOR

Laila Silamikele

showing 3 related works from this author

First Report on the Latvian SARS-CoV-2 Isolate Genetic Diversity

2021

Remaining a major healthcare concern with nearly 29 million confirmed cases worldwide at the time of writing, novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused more than 920 thousand deaths since its outbreak in China, December 2019. First case of a person testing positive for SARS-CoV-2 infection within the territory of the Republic of Latvia was registered on 2nd of March 2020, 9 days prior to the pandemic declaration by WHO. Since then, more than 277,000 tests were carried out confirming a total of 1,464 cases of coronavirus disease 2019 (COVID-19) in the country as of 12th of September 2020. Rapidly reacting to the spread of the infection, an ongoing sequenci…

0301 basic medicineHCoV-19Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.disease_cause03 medical and health sciences0302 clinical medicinePandemicmedicineChinaOriginal ResearchCoronavirusGenetic diversitylcsh:R5-920SARS-CoV-2LatvianOutbreakCOVID-19General Medicinegenetic diversityVirologyLatvialanguage.human_language030104 developmental biologyGeography2019-nCoVlanguageMedicinenext-generation sequencingSevere acute respiratory syndrome coronaviruslcsh:Medicine (General)030217 neurology & neurosurgeryFrontiers in Medicine
researchProduct

Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response

2020

Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naive volunteers with type 2 diabetes in vivo. The longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholester…

0301 basic medicineMaleendocrine system diseasesMolecular biologyGene ExpressionType 2 diabetesPharmacologyBiochemistryTranscriptome0302 clinical medicineEndocrinologyMedical ConditionsSequencing techniquesGastrointestinal CancersBreast TumorsMedicine and Health SciencesHomeostasisEnergy-Producing OrganellesWhole bloodMultidisciplinarySmall nuclear RNABiguanideQRRNA sequencingGenomicsMiddle AgedMetforminMetforminMitochondriaType 2 DiabetesNucleic acidsCholesterolSmall nucleolar RNAOncology030220 oncology & carcinogenesisMedicineFemaleCellular Structures and OrganellesTranscriptome Analysismedicine.drugResearch Articlemedicine.drug_classEndocrine DisordersScienceGastroenterology and HepatologyBioenergetics03 medical and health sciencesBreast CancermedicineGeneticsDiabetes MellitusHumansNon-coding RNAGlycemicAgedbusiness.industryGene Expression ProfilingType 2 Diabetes Mellitusnutritional and metabolic diseasesBiology and Life SciencesComputational BiologyCancers and NeoplasmsCell Biologymedicine.diseaseGenome AnalysisGene regulationGene expression profilingResearch and analysis methods030104 developmental biologyMolecular biology techniquesMetabolic DisordersRNAbusinessBlood Chemical AnalysisPLoS ONE
researchProduct

Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients

2020

BackgroundThe study was conducted to investigate the effects of metformin treatment on the human gut microbiome's taxonomic and functional profile in the Latvian population, and to evaluate the correlation of these changes with therapeutic efficacy and tolerance.MethodsIn this longitudinal observational study, stool samples for shotgun metagenomic sequencing-based analysis were collected in two cohorts. The first cohort included 35 healthy nondiabetic individuals (metformin dose 2x850mg/day) at three time-points during metformin administration. The second cohort was composed of 50 newly-diagnosed type 2 diabetes patients (metformin dose-determined by an endocrinologist) at two concordant ti…

AdultMale0301 basic medicinemedicine.medical_specialtyendocrine system diseasesSciencePopulationPrevotella030209 endocrinology & metabolismType 2 diabetesGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineLongitudinal StudiesMicrobiomeeducationeducation.field_of_studyMultidisciplinarybiologyBacteroidetesbusiness.industryMicrobiotaQTherapeutic effectRnutritional and metabolic diseasesmedicine.diseasebiology.organism_classificationMetforminGastrointestinal MicrobiomeMetforminLactococcus lactis030104 developmental biologyDiabetes Mellitus Type 2CohortMedicineDialisterFemalebusinessResearch Articlemedicine.drugEnterococcus faeciumPLOS ONE
researchProduct